Advertisement

Topics

Latest "Rosuvastatin Placebo Critically" News Stories

21:06 EDT 20th June 2018 | BioPortfolio

Here are the most relevant search results for "Rosuvastatin Placebo Critically" found in our extensive news archives from over 250 global news sources.

More Information about Rosuvastatin Placebo Critically on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Rosuvastatin Placebo Critically for you to read. Along with our medical data and news we also list Rosuvastatin Placebo Critically Clinical Trials, which are updated daily. BioPortfolio also has a large database of Rosuvastatin Placebo Critically Companies for you to search.

Showing "Rosuvastatin Placebo Critically" News Articles 1–25 of 1,000+

Wednesday 20th June 2018

Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials

Bagsværd, Denmark, 20 June 2018 - Novo Nordisk today announced the successful completion and headline results of the phase 3a trials PIONEER 4 comparing oral semaglutide as a treatment for adults with type 2 diabetes to Victoza® (1.8 mg liraglutide) and placebo, and PIONEER 7 comparing oral semaglutide as a treatment for adults with type 2 diabetes to sitagliptin 100 mg. Oral s...


Anika’s Drug Combo Fails to Meet Primary Endpoint in Phase 3 Trial in Knee Osteoarthritis

BEDFORD, Mass.–(BUSINESS WIRE)–Jun. 19, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support...

TransMed7, LLC Announces 510(k) Clearance by the U.S. FDA for its SpeedBird Soft Tissue Biopsy Device Platform

TransMed7, LLC announced today that the United States Food and Drug Administration (FDA) has cleared its 510(k) application for the company to market the SpeedBirdTM platform of soft tissue biopsy devices. “We are delighted to announce this 510(k) clearance by the FDA,” stated Dr. James W. Vetter, TransMed7 Co-Founder and Chairman. “This is an import...


Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management

Idorsia Pharmaceuticals Ltd. / Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Idorsia to host an investor webcast to discuss the Phase 3 program today at 14:00hrs CEST              Al...

Biotest AG: Biotest AG opens third plasma collection centre in Czech Republi

DGAP-News: Biotest AG / Key word(s): Miscellaneous 20.06.2018 / 07:00 The issuer is solely responsible for the content of this announcement. / PRESS RELEASE Biotest AG opens third plasma collection centre in Czech Republic - 19 plasma collection centres in Europe to ensure long-term plasma supply Dreieich, 20 June 2018. Biotest received an operating permit for its third plasma coll...

GenSight Biologics : Key Opinion Leaders Highlight GS010 Efficacy and Patient Benefits in Discussion of Findings from REVERSE Phase III Clinical Trial

Preservation of anatomic structures combined with visual function improvement (contrast sensitivity) demonstrate neuro-protection in human genetic disease Bilateral improvement deemed clinically relevant and not the result of placebo effect or natural history GenSight committed to push GS010 through regulatory a...

Tuesday 19th June 2018

Gene transfer rules written in DNA

A team led by a New Zealand researcher has discovered that bacteria’s ability to transfer genes, like those associated with antibiotic resistance, is governed by a previously unknown set of rules that are written in the DNA of the recipient. Dr Heather Hendrickson, of Massey’s Institute of Natural and Mathematical Sciences, made the discovery along with a team of scientists from the Univers...

Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis

CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. approval Strong pain reduction and overall symptom relief consistent with statistically significant results of CINGAL 13-01 Phase III placebo-controlled clinical s...

Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan

– Expects to submit NDA for KPI-121 0.25% in the second half of 2018 – – Expects to initiate Phase 3 STRIDE 3 trial in the third quarter of 2018 – Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term tre...

AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in prostate cancer

Paris, June 19, 2018, 7pm AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recomm...

Intramuscular Steroid Injections for Hip Osteoarthritis?

A single IM injection improved pain modestly compared with placebo.

[Articles] Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

Rasagiline was safe in patients with amyotrophic lateral sclerosis. There was no difference between groups in the primary outcome of survival, although post-hoc analysis suggested that rasagiline might modify disease progression in patients with an initial slope of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised greater than 0·5 points per month at baseline. This should be confirmed...

Tamsulosin Ineffective for Small Ureteral Stones

The passage rate for ureteral stones less than 9 mm in diameter did not differ significantly between tamsulosin and placebo recipients, study finds.

Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial

Accumulated safety data to date continues to indicate a favorable drug safety profile without hepatotoxicity Namodenoson has an Orphan Drug Designation in Europe and the U.S., as well as Fast Track Status in the U.S. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a ...

AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018

Key data evaluating the efficacy and safety of dapagliflozin in combination with other type 2 diabetes therapies head-to-head vs. insulin or sulfonylurea Latest data from the DEPICT clinical program evaluating dapagliflozin to address an unmet need for oral therapy in adult patients with type 1 diabetes Debut of pre-clinical and cl...

Alpha-blockers Do Not Promote Passage of Urinary Stones

A new study adds to evidence that alpha-blockers do not expedite the passage of ureteral stones in patients who present with renal colic compared with placebo, although stone size may matter. Medscape Medical News

Karuna Receives $8 Million Wellcome Trust Award to Advance First-in-Class Phase 2 Clinical Program in Schizophrenia

Karuna’s proprietary approach leverages novel mechanism to treat psychosis and cognition in mental health conditions Karuna Pharmaceuticals, an affiliate of PureTech He

Monday 18th June 2018

ThoraQuik Launch

Members of the British Association for Immediate Care at their Conference in Coventry welcomed the launch of a new medical product ThoraQuik® designed to save lifes, and in particular those of our service personnel in Afghanistan. Bomb blast, shrapnel and bullet wounds can all allow air into space between the chest wall and the lungs (a pneumothorax). If the hole acts like a flap valve then th...

Renovo announces major restructuring

Renovo Group plc (LSE: RNVO) announced on 11 February 2011 that its first EU Phase III trial for Juvista® in scar revision surgery (REVISE™) did not meet its primary or secondary endpoints.  Renovo has now conducted further exploratory analyses of the results of that trial and its implications for Juvista. The further exploratory analyses have revealed: -    &nbs...

MHRA launches its new Notification Scheme

MHRA launches its new Notification Scheme for certain types of clinical trial. Normally the Medicines and Healthcare products Regulatory Agency (“MHRA”) will provide an initial response to an application for a clinical trial authorisation (“CTA”) within 30 days of date of receipt of application. However, on 1 April 2011, the MHRA launched its new Notification Scheme for cer...

Successful Juvista Trial

New Paediatric and Existing Adult Formulations Demonstrate Statistically Significant Improvements in Scar Appearance Compared to Placebo Renovo Group plc (LSE : RNVO), the biopharmaceutical company developing drugs to reduce scarring, improve wound healing and enhance tissue regeneration, today announces  a successful outcome of its clinical trial designed to establish the safety and efficacy...

Launch of ThoraQuik® for pneumothorax and pleural effusions

Medical Device Innovations Ltd of Daresbury Innovation Centre is pleased to announce the launch of their ThoraQuik® device for the treatment of pneumothorax and pleural effusions. The product will be marketed by Bound Tree Medical Europe Ltd.Conceived by Dr Iain McNeil a past Chairman of the British Association for Immediate Care (BASICS) from his extensive experience attending the critic...

BIA and Bionow welcome the publication of the UK government antimicrobial resistance strategy

The strategy will help to put the challenge of antimicrobial resistance on the global agenda. Along with events such as BioInfect 2013 which is to be hosted by Bionow and BioHub on 26th November 2013 we hope this will stimulate extensive debate and action regarding the challenges which the development of resistance presents.Steve Bates, BioIndustry Association (BIA) Chief Executive Officer, said "...

Euprotec secures £165k Corridor Growth Fund grant

Specialist contract research organisation (CRO), Euprotec, has been awarded £165,000 from the Corridor Growth Fund (CGF) in order to fuel its expansion plans, as it broadens its anti-infective drug discovery and development capabilities.   Supported by the Government’s Regional Growth Fund, the £2 million CGF provides grant funding to qualifying applicants, helping to u...

The Bionow blog: The “Witty Report” – a recipe for success and anti-microbial resistance a challenge reminiscent of the dark ages when a scratch could kill.

Given the importance of both the Witty report and anti-microbial resistance the Bionow blog is focusing on just two major issues in this edition.‘Smart Specialisation’ or doing what you are good at provides the strongest basis for regional economic growth. In his recent review Sir Andrew Witty asserts that, ‘much of the UK’s comparative economic advantage in the twenty-firs...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks